Marshall Wace LLP Purchases 178,548 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Marshall Wace LLP lifted its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 111.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 338,259 shares of the company's stock after buying an additional 178,548 shares during the period. Marshall Wace LLP owned about 0.28% of Privia Health Group worth $6,613,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PRVA. First Horizon Advisors Inc. grew its position in shares of Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after buying an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Privia Health Group by 7,833.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. acquired a new stake in Privia Health Group during the 4th quarter valued at approximately $51,000. Quadrant Capital Group LLC raised its holdings in Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after purchasing an additional 511 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock worth $98,000 after purchasing an additional 3,249 shares during the period. 94.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 5,630 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the transaction, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Stock Down 0.2 %

PRVA traded down $0.04 during trading on Tuesday, hitting $23.16. 53,798 shares of the company's stock were exchanged, compared to its average volume of 771,290. The stock has a market cap of $2.81 billion, a P/E ratio of 232.06, a PEG ratio of 3.47 and a beta of 0.88. The business's 50 day moving average is $23.60 and its two-hundred day moving average is $21.97. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Truist Financial increased their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. Robert W. Baird upped their target price on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Canaccord Genuity Group lifted their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Barclays increased their price target on Privia Health Group from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $27.14.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.